Estimation of the Eligible Population For Resmetirom Among Adults in the United States for Treatment of Non-Cirrhotic NASH with Moderate-to-Advanced Liver Fibrosis

Hepatology

Prevalence of metabolic dysfunction-associated steatotic liver disease and fibrosis defined by liver elastography in the United States using National Health and Nutrition examination survey 2017-march 2020 and august 2021-august 2023 data

Hepatology

Unalp-Arida A, Ruhl CE

doi: 10.1097/HEP.0000000000001211

Hepatology

Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA

Gut

Yang AH, Tincopa MA, Tavaglione F, Ajmera VH, Richards LM, Amangurbanova M, Butcher C, Hernandez C, Madamba E, Singh S, Bettencourt R, Schnabl B, Sirlin CB, Loomba R

doi: 10.1136/gutjnl-2024-332917

Hepatology

Epidemiology of compensated Advanced Chronic Liver Disease (cACLD) in the United States: Insights from NHANES 2017-2020

Clin Gastroenterol Hepatol

Goyal RM, Doshi A, Rao S, Arora K, Maheshwari S, Gaglio P

doi: 10.1016/j.cgh.2025.06.010

Hepatology

Non-invasive assessment of severe liver fibrosis in patients with Fontan-associated liver disease: The VALDIG-EASL FONLIVER cohort

J Hepatol

Téllez L, Rincón D, Payancé A, Jaillais A, Lebray P, Rodríguez de Santiago E, Clemente A, Paradis V, Lefort B, Garrido-Lestache E, Prieto R, Iserin L, Tallegas M, Garrido E, Torres M, Muriel A, Perna C, Jesús Del Cerro M, d'Alteroche L, Rautou PE, Bañares R, Albillos A, VALDIG-EASL consortium

doi: 10.1016/j.jhep.2024.09.005

Hepatology

Optimal population screening strategies for liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease

Am J Gastroenterol

Kim WR, Mannalithara A, Charu V, Chung N, Kwong A, Kwo PY, Torok NJ, Asch SM, Kim SH

doi: 10.14309/ajg.0000000000003268

Further Publications

Screening for advanced liver fibrosis due to metabolic dysfunction-associated steatotic liver disease alongside retina scanning in people with type 2 diabetes: a cross-sectional study

Lancet Gastroenterol Hepatol

Lindfors A, Strandberg R, Hagström H

doi: 10.1016/S2468-1253(24)00313-3

Hepatology

Effectiveness of a model of care based on Fibrosis-4 and liver stiffness measurement for the screening of patients with type 2 diabetes mellitus at risk of advanced liver disease: results from an Italian prospective multicentre study

Am J Gastroenterol

Caviglia GP, Ferro A, D'Ambrosio R, Perbellini R, Lampertico P, Periti G, Valenti L, Ciccioli C, Pennisi G, Petta S, Brodosi L, Petroni ML, Marchignoli F, Pironi L, Sagripanti A, Argenziano ME, Svegliati-Baroni G, Rosso C, Barutta F, Armandi A, Gruden G, Bugianesi E

doi: 10.14309/ajg.0000000000003493

Hepatology

Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study

Lancet Gastroenterol Hepatol

Jachs M, Odriozola A, Turon F, Moga L, Téllez L, Fischer P, Saltini D, Kwanten WJ, Grasso M, Llop E, Mendoza YP, Armandi A, Thalhammer J, Pardo C, Colecchia A, Ravaioli F, Maasoumy B, Laleman W, Presa J, Schattenberg JM, Berzigotti A, Calleja JL, Calvaruso V, Francque S, Schepis F, Procopet B, Albillos A, Rautou PE, García-Pagán JC, Puente Á, Fortea JI, Reiberger T, Mandorfer M, SSM-100Hz/ACLD Study Group, Baveno Cooperation

doi: 10.1016/S2468-1253(24)00234-6

Hepatology

Steatotic liver disease classification is dynamic, affecting clinical trial eligibility and subclass-specific treatments

Clin Gastroenterol Hepatol

Israelsen M, Thorhauge KH, Andersen P, Johansen S, Schnefeld HL, Bech KT, Hansen JK, Torp N, Jensen EL, Hansen ED, Spedtsberg IZ, Villesen IF, Hansen CD, Hansen T, Lindvig KP, Thiele M, Krag A

doi: 10.1016/j.cgh.2025.02.007

Related content

Prevalence of metabolic dysfunction-associated steatotic liver disease and fibrosis defined by liver elastography in the United States using National Health and Nutrition examination survey 2017-march 2020 and august 2021-august 2023 data

Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA

Epidemiology of compensated Advanced Chronic Liver Disease (cACLD) in the United States: Insights from NHANES 2017-2020

Non-invasive assessment of severe liver fibrosis in patients with Fontan-associated liver disease: The VALDIG-EASL FONLIVER cohort

Optimal population screening strategies for liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease

Screening for advanced liver fibrosis due to metabolic dysfunction-associated steatotic liver disease alongside retina scanning in people with type 2 diabetes: a cross-sectional study

Effectiveness of a model of care based on Fibrosis-4 and liver stiffness measurement for the screening of patients with type 2 diabetes mellitus at risk of advanced liver disease: results from an Italian prospective multicentre study

Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study

Steatotic liver disease classification is dynamic, affecting clinical trial eligibility and subclass-specific treatments